<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>238458</rcn>
  <id>101044990</id>
  <acronym>BrainCRISPR</acronym>
  <teaser>Genetic brain diseases are among the most devastating and fatal diseases, typically having only palliative treatments and no cure. The revolutionary CRISPR/Cas gene editing technology provides a new horizon and enormous potential for treating such diseases. However, efficient...</teaser>
  <objective>Genetic brain diseases are among the most devastating and fatal diseases, typically having only palliative treatments and no cure. The revolutionary CRISPR/Cas gene editing technology provides a new horizon and enormous potential for treating such diseases. However, efficient and safe delivery of CRISPR machinery to diseased cells within the brain is one of the greatest challenges in medicine today. Here, I plan to expand far beyond the state-of-the-art, and propose a game-changer approach for this unmet need: A breakthrough nanoplatform, which will transform CRISPR into a clinically-relevant, non-invasive technology, enabling therapeutic genome editing in the brain. Our proof-of-concept results serve as the baseline of this pioneering research project, revealing the exceptional capabilities of insulin as a key to overcoming formidable brain and cell barriers. We will harness these unique abilities within the novel nanoplatform, and shuttle CRISPR machinery across the blood-brain barrier, transport it into deep brain regions, and mediate its successful entry into specific diseased brain cells, leading to highly effective gene editing. The nanoplatform will be designed to meet key criteria for non-invasive, safe and efficient delivery of CRISPR to the brain, while conferring a high degree of modularity and compositional heterogeneity - thus providing both universal and patient-specific components. The nanoplatform will be thoroughly investigated in primary brain cells, 3D organoids, and case-studies of monogenic brain disease models. This comprehensive research will culminate with a universal and modular BrainCRISPR nanoplatform, and delineate design principles for its precise tailoring to specific needs of different brain diseases. Overall, this research will provide in-depth fundamental knowledge and have a transformative effect on applying CRISPR in brain, whilst opening a wide array of possibilities with broader impact on genetic brain therapy and beyond.</objective>
  <title>In Vivo CRISPR-Based Nanoplatform for Gene Editing:  A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases</title>
  <totalCost>2249895</totalCost>
  <ecMaxContribution>2249895</ecMaxContribution>
  <startDate>2022-06-01</startDate>
  <endDate>2027-05-31</endDate>
  <ecSignatureDate>2022-05-30</ecSignatureDate>
  <duration>60</duration>
  <status>SIGNED</status>
  <keywords>Nanoparticles for drug delivery, nanotechnology,  nanomedicine, CRISPR, drug delivery to the brain</keywords>
  <identifiers>
    <grantDoi>10.3030/101044990</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2025-01-03 10:47:16</sourceUpdateDate>
  <contentCreationDate>2022-07-26 20:01:34</contentCreationDate>
  <contentUpdateDate>2022-09-04 00:45:20</contentUpdateDate>
  <lastUpdateDate>2025-11-03 09:43:57</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <rcn>434701</rcn>
        <id>434701-gene-editing-nanotechnology-for-personalised-brain-therapy</id>
        <title>Gene-editing nanotechnology for personalised brain therapy</title>
        <contentUpdateDate>2022-10-18 15:48:29</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode>/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode>/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55314</rcn>
        <title>ERC-2021-COG</title>
        <identifier>ERC-2021-COG</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55314</rcn>
        <title>ERC-2021-COG</title>
        <identifier>ERC-2021-COG</identifier>
      </call>
      <organization netEcContribution="2249895" totalCost="2249895" source="corda" order="1" ecContribution="2249895" terminated="false" sme="false" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>1908478</rcn>
        <id>999886574</id>
        <vatNumber>IL580063683</vatNumber>
        <legalName>BAR ILAN UNIVERSITY</legalName>
        <shortName>BIU</shortName>
        <address>
          <street>BAR ILAN UNIVERSITY CAMPUS</street>
          <city>Ramat Gan</city>
          <postalCode>52900</postalCode>
          <country>IL</country>
          <postBox>N/A</postBox>
          <url>http://www1.biu.ac.il/</url>
          <geolocation>32.0724892,34.824244</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/HES</code>
              <title>Higher or Secondary Education Establishments</title>
              <displayCode>/Higher or Secondary Education Establishments</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Israel</name>
              <rcn>307661352</rcn>
              <nutsCode>IL</nutsCode>
              <euCode>IL</euCode>
              <isoCode>IL</isoCode>
            </region>
            <region type="relatedRegion">
              <name>Israel</name>
              <rcn>307661352</rcn>
              <nutsCode>IL</nutsCode>
              <euCode>IL</euCode>
              <isoCode>IL</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>705886</rcn>
        <id>HORIZON_ERC-2021-COG</id>
        <code>ERC-2021-COG</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>ERC CONSOLIDATOR GRANTS</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705727</rcn>
        <id>HORIZON.1.1</id>
        <code>HORIZON.1.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.1.1</pga>
        <title>European Research Council (ERC)</title>
        <parent>
          <programme>
            <rcn>705726</rcn>
            <code>HORIZON.1</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1267542</rcn>
        <id>101044990_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - BrainCRISPR (In Vivo CRISPR-Based Nanoplatform for Gene Editing:  A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases)</title>
        <description>periodic</description>
        <teaser>The revolutionary CRISPR/Cas genome editing technology has enormous potential for treating many genetic diseases. However, delivery of CRISPR machinery to diseased cells within the brain is one of the greatest challenges in medicine today. The ERC Consolidator-funded...</teaser>
        <sourceUpdateDate>2025-03-11 17:47:16</sourceUpdateDate>
        <contentUpdateDate>2025-03-11 17:47:16</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode>/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1161389</rcn>
        <id>101044990_40481_PUBLIHORIZON</id>
        <title>Antibody Delivery into the Brain by Radiosensitizer Nanoparticles for Targeted Glioblastoma Therapy</title>
        <details>
          <authors>Omer Gal; Oshra Betzer; Liat Rousso-Noori; Tamar Sadan; Menachem Motiei; Maxim Nikitin; Dinorah Friedmann-Morvinski; Rachela Popovtzer; Aron Popovtzer</authors>
          <journalTitle>Journal of Nanotheranostics</journalTitle>
          <publishedPages></publishedPages>
          <publishedYear>2022</publishedYear>
          <publisher>MDPI</publisher>
        </details>
        <identifiers>
          <issn>2624-845X</issn>
          <doi>10.5281/zenodo.12625784</doi>
        </identifiers>
        <sourceUpdateDate>2024-07-17 10:14:56</sourceUpdateDate>
        <contentUpdateDate>2024-09-02 10:32:06</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/publication</code>
              <title>Project publication</title>
              <description>Result: Project publications</description>
              <displayCode>/Project publication</displayCode>
            </category>
            <category classification="projectPublication" type="isPublishedAs">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/PEER_REVIEWED_ARTICLE</code>
              <title>Peer reviewed articles</title>
              <displayCode>/Peer reviewed articles</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1259545</rcn>
        <id>101044990_130447_PUBLIHORIZON</id>
        <title>Impact of synthesis methods on the functionality of antibody-conjugated gold nanoparticles for targeted therapy</title>
        <details>
          <authors>Adi Anaki, Chen Tzror-Azankot, Menachem Motiei, Tamar Sadan, Rachela Popovtzer</authors>
          <journalNumber>6</journalNumber>
          <journalTitle>Nanoscale Advances</journalTitle>
          <publishedPages></publishedPages>
          <publishedYear>2024</publishedYear>
          <publisher>Royal Society of Chemistry (RSC)</publisher>
        </details>
        <identifiers>
          <issn>2516-0230</issn>
          <doi>10.1039/D4NA00134F</doi>
        </identifiers>
        <sourceUpdateDate>2025-04-15 01:27:45</sourceUpdateDate>
        <contentUpdateDate>2025-05-28 13:46:00</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/publication</code>
              <title>Project publication</title>
              <description>Result: Project publications</description>
              <displayCode>/Project publication</displayCode>
            </category>
            <category classification="projectPublication" type="isPublishedAs">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/PEER_REVIEWED_ARTICLE</code>
              <title>Peer reviewed articles</title>
              <displayCode>/Peer reviewed articles</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/37/165/659</code>
        <title>gene therapy</title>
        <displayCode>/medical and health sciences/medical biotechnology/genetic engineering/gene therapy</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/37/171</code>
        <title>nanomedicine</title>
        <displayCode>/medical and health sciences/medical biotechnology/nanomedicine</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/225</code>
        <title>oncology</title>
        <displayCode>/medical and health sciences/clinical medicine/oncology</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/23/49/337/1025</code>
        <title>genomes</title>
        <displayCode>/natural sciences/biological sciences/genetics/genomes</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-ERC</code>
        <title>HORIZON ERC Grants</title>
        <description>HORIZON ERC Grants</description>
        <displayCode>/HORIZON ERC Grants</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>